Stock Events

Stock Events

Search...

Avidity Biosciences

$13.04

0

-$0.07-0.53% Today

Statistics

Day High

13.36

Day Low

13.03

52W High

-

52W Low

-

Volume

490

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

12MayExpected

Q3 2025

Q4 2025

Next

-1.3

-1.23

-1.16

-1.09

Expected EPS

-1.294117

Actual EPS

N/A

Financials

-3,650.39%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

37.51MRevenue

-1.37BNet Income

Analyst Ratings

$66.22Average Price Target

The highest estimate is 74.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.

Buy

10%

Hold

90%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Sarepta Therapeutics

Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.

Ionis Pharmaceuticals

Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.

Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.

BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.

CRISPR Therapeutics

CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.

Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

About

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Show more...

CEO

ISIN

US05370A1088

Listings

0 Comments

Share your thoughts

FAQ

What is Avidity Biosciences stock price today?▼

The current price of RNA.BOATS is $13.04 USD — it has decreased by -0.53% in the past 24 hours. Watch Avidity Biosciences stock price performance more closely on the chart.

What is Avidity Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Avidity Biosciences stocks are traded under the ticker RNA.BOATS.

When is the next Avidity Biosciences earnings date?▼

Avidity Biosciences is going to release the next earnings report on May 12, 2026.

What is Avidity Biosciences revenue for the last year?▼

Avidity Biosciences revenue for the last year amounts to 37.51M USD.

What is Avidity Biosciences net income for the last year?▼

RNA.BOATS net income for the last year is -1.37B USD.

When did Avidity Biosciences complete a stock split?▼

Avidity Biosciences has not had any recent stock splits.